News
Cadonilimab Yields 100% 24-Month OS in Recurrent Cervical Cancer Population
7+ hour, 3+ min ago (548+ words) Cadonilimab monotherapy did not yet reach the median OS or PFS at the time of data cutoff for these patients with recurrent or metastatic cervical cancer. The analysis included 99 efficacy-evaluable patients with a median follow-up of 26.5 months. Investigators stratified outcomes…...
FDA Grants Approval to Teclistamab Combo in RRMM
8+ hour, 21+ min ago (269+ words) The FDA granted approval to teclistamab-cqyv (Tecvayli) in combination with daratumumab hyaluronidase-fihj as a treatment for adults with relapsed/refractory multiple myeloma after at least 1 prior line of therapy, according to a release from the agnecy.1 The FDA approved this…...
Updated Zenocutuzumab Analysis Reveals “Striking” Outcomes in NRG1+ NSCLC
12+ hour, 56+ min ago (140+ words) In a discussion with CancerNetwork, Zhaohui Liao Arter, MD, spoke about updated analysis findings from the phase 2 eNRGy trial (NCT02912949) assessing zenocutuzumab-zbco (Bizengri) beyond initial disease progression among patients with NRG1 fusion-positive non'small cell lung cancer. Data on 27 evaluable patients revealed "encouraging…...
Trifluridine/Tipiracil-Associated Neutropenia Associated With Improved Outcomes in mCRC
16+ hour, 1+ min ago (376+ words) According to Marwan G. Fakih, MD, neutropenia may be a biomarker of benefit for patients with metastatic colorectal cancer receiving trifluridine/tipiracil and bevacizumab. In a conversation with Marwan G. Fakih, MD, he noted that while the relationship between hematologic toxicity and…...
Namodenoson Meets Primary Safety End Point in Pretreated PDAC
16+ hour, 31+ min ago (605+ words) Namodenoson did not exhibit any new safety signals or unexpected toxicity as a treatment for patients with PDAC who progressed on at least 1 systemic therapy. Namodenoson (CF102) successfully met its primary end point of safety and tolerability in a phase 2a trial…...
The Truth About GLP-1s: Assessing the Risk of Medullary Thyroid Cancer in Humans
1+ day, 1+ hour ago (143+ words) Gary Clayman, MD, explained that while animal studies have suggested a link between GLP-1 therapies and C-cell issues leading to medullary thyroid cancer, these findings have not been replicated in human studies. Despite the lack of human evidence, the potential…...
The Evolving Landscape of Immunotherapy in Breast Cancer
1+ day, 7+ hour ago (170+ words) Sarah Poland, MD, discussed the landscape of immunotherapy in breast cancer, including clinical trial data, the rise of ADCs, and strategies for managing AEs. Manmeet Ahluwalia, MD, MBA Shaina Rozell, MD, MPH; Seth A. Wander, MD, PhD Hope S. Rugo, MD, FASCO;…...
New Zenocutuzumab Findings Provide Hope for Targeting Rare NSCLC Subtypes
1+ day, 10+ hour ago (257+ words) An updated analysis of the eNRGy trial showed that zenocutuzumab may provide meaningful benefit beyond initial disease progression. Third, the safety profile supports extended treatment, with no discontinuation due to adverse events, even in patients treated for over 3 years. We…...
FDA Grants Pre-Market Approval to AI Device for Breast Cancer Surgery
1+ day, 12+ hour ago (467+ words) A pre-determined change control plan was authorized as part of the pre-market approval, allowing for AI enhancements without the need for FDA oversight. The FDA has granted pre-market approval to Claire (formerly known as Perimeter OCT B-Series with ImgAssist AI…...
What Should Patients With mCRC Consider When Deciding Treatment Options?
1+ day, 13+ hour ago (326+ words) Patients with metastatic colorectal cancer who desire better disease control are best served with trifluridine/tipiracil plus bevacizumab, according to Marwan G. Fakih, MD. While disease control is paramount, the mode of administration often dictates the therapeutic path. Fruquintinib offers a distinct…...